Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998;25:11-18.

2. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-1828.

3. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and Bax. J Immunol 1996;156:2624-2630.

4. Pepper C, Bentley P, Hoy T. Regulation of clinical chemo-resistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia cells. Blood 1997;89:3378-3384.

5. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein activating factor-1 mediated caspase pathway. J Biol Chem 2000;275:29-34.

6. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome C and ATP-dependent formation of APAF-1 caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.

7. Rou'e G, Lancry L, Duquesne F, Salaun V, Troussard X, Sola B. Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia. Leuk Res 2001;25:967-980.

8. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-a-induced apoptosis by NF-kB. Science 1996;274:788-789.

9. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2 Chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome C. Proc Natl Acad Sci USA 1998;95:9567-9571.

10. Zapata JM, Krajewska M, Krajewska S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000;165:5084-5096.

11. Furman RR, Asgary Z, Mascarenhas JO, Schattner EJ. Modulation of NF-Kb activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-2206.

12. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT)1 and STAT 3 constitutively phosphorylated on serine residues. J Clin Invest 1997;100:3140-3148.

13. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999;5:444-447.

14. Webb A, Cunningham D, Clarke PA, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-1141.

15. Wang J-L, Liu D, Zhang Z-J, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-7129.

16. Kitada S, Zapata JM, Andreeff M, Reed C. Protein kinase inhibitors flavopiridol and 7-hydroxy staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-397.

17. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:55-162.

18. Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol 1999;15:793-802.

19. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002;29:10-24.

20. Jurlander J. The cellular biology of B-cell chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1998;27: 29-52.

21. Ball KL, Lain S, Fahraeus R, Smythe C, Lane DP. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21 WAF1. Curr Biol 1997;7:71-80.

22. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-387.

23. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-3816.

24. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowitz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999;59:5433-5437.

25. Saenaeve C, Kazanietz MG, Blumberg PM, et al. Differential inhibition of PKC isozymes by UCN-01, a staurosporine analog. Mol Pharmacol 1994;45:1207-1214.

26. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-397.

27. Yamauchi T, Keating MJ, Plunkett W. UCN-01(7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther 2002;1: 287-294.

28. Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000;6:825-828.

29. Varterasian ML, Mohammad RM, Eilender DS, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998;16:56-62.

30. Ueda H, Nakajima H, Hori Y, et al. Depsipeptide: a novel antitumor bicyclic depsipeptide produced by Chromo-bacterium violaceum no. 968. Taxonomy, fermentation, isolation, physico-chemica 1, and biological properties, and antitumor activity. J Antibiotics 1994;47:301-310.

31. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241:126-133.

32. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition, a new strategy in cancer treatment. Invest New Drugs 2000;18:109-121.

33. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000;275:36,062-36,066.

34. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517-522.

35. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(suppl 2): 2-9.

36. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-2170.

37. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961-2966.

38. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29:36-40.

39. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multi-center study of human CD52 antibody in previously treated chronic lymphocytic leukemia, European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567.

40. Higaki Y, Hata D, Kanazashi S, et al. Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class antibodies. Immunol Cell Biol 1994;72:205-214.

41. Link BK, Wang H, Byrd JC, et al. Phase I trial of humanized 1D10 (Apolizumab) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma. Proc Am Soc Clin Oncol 2000;19:24a (abstract 86).

42. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and HU1D10 (apolizumab). Semin Oncol 2002;29(suppl 2):81-86.

43. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia. N Engl J Med 2001;345:241-247.

44. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of Iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.

45. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 Ibritumomab Tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002;29:87-92.

46. Kipps TJ. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol 2002;29(suppl 2): 98-104.

47. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999;93:1992-2002.

48. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998;101:1133-1141.

Was this article helpful?

0 0
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book

Post a comment